These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 35157894)

  • 1. Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination.
    Flahault A; Touchard J; Péré H; Ulrich L; Sabatier B; Veyer D; Lebeaux D; Thervet E
    Kidney Int; 2022 Apr; 101(4):824-825. PubMed ID: 35157894
    [No Abstract]   [Full Text] [Related]  

  • 2. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme.
    Ducloux D; Courivaud C
    Kidney Int; 2022 Mar; 101(3):645-646. PubMed ID: 34995651
    [No Abstract]   [Full Text] [Related]  

  • 3. In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d.
    Lau D; Saxinger L
    Ann Intern Med; 2022 Jan; 175(1):JC5. PubMed ID: 34978854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
    Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
    Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
    Takemoto K
    Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of REGEN-COV administration and progression to severe COVID-19.
    Kadowaki T; Imajou S; Matsumoto N; Takao S; Yorifuji T
    J Infect Chemother; 2022 Nov; 28(11):1459-1463. PubMed ID: 35817250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 Therapeutics and Vaccines: A Race to Save Lives.
    Bebenek I; Bannister R; Dubinion J; Fortin M; Liu M; Motter AL; Rohde CM; Wrzesinski C
    Toxicol Sci; 2022 Jan; 185(2):119-127. PubMed ID: 34735018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
    Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Audio Interview: Covid-19 Vaccination and the Omicron Variant.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(27):e102. PubMed ID: 34965346
    [No Abstract]   [Full Text] [Related]  

  • 10. Bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19.
    Med Lett Drugs Ther; 2021 Oct; 63(1635):163-164. PubMed ID: 35050242
    [No Abstract]   [Full Text] [Related]  

  • 11. Eua for Regen-Cov Now Includes COVID-19 Postexposure Prophylaxis.
    Aschenbrenner DS
    Am J Nurs; 2021 Nov; 121(11):22. PubMed ID: 34673689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
    Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
    Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
    Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mix-and-match COVID vaccines: the case is growing, but questions remain.
    Lewis D
    Nature; 2021 Jul; 595(7867):344-345. PubMed ID: 34211168
    [No Abstract]   [Full Text] [Related]  

  • 16. In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron.
    Hu YF; Hu JC; Chu H; Yau T; Zhang BZ; Huang JD
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron likely to weaken COVID vaccine protection.
    Callaway E
    Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
    [No Abstract]   [Full Text] [Related]  

  • 18. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
    Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
    N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
    [No Abstract]   [Full Text] [Related]  

  • 19. Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
    Servellita V; Morris MK; Sotomayor-Gonzalez A; Gliwa AS; Torres E; Brazer N; Zhou A; Hernandez KT; Sankaran M; Wang B; Wong D; Wang C; Zhang Y; Reyes KR; Glasner D; Deng X; Streithorst J; Miller S; Frias E; Rodgers M; Cloherty G; Hackett J; Hanson C; Wadford D; Philip S; Topper S; Sachdev D; Chiu CY
    Nat Microbiol; 2022 Feb; 7(2):277-288. PubMed ID: 35013591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SARS-CoV-2 neutralizing monoclonal antibodies: a potential breakthrough in the early treatment of Covid-19 in high-risk patients].
    de Bree GJ; Wiersinga WJ
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.